Byondis
Ronald Smulders is a seasoned professional in analytical development and quality control, currently serving as Senior Director at Byondis since September 2016, where responsibilities include managing a department of approximately 80 staff and overseeing the analytical development of innovative complex protein products, including method development and validation. Prior to Byondis, Ronald held various roles at Merck, rising from Director to Executive Director, managing substantial teams and focusing on late-stage analytical development of recombinant protein products. Earlier career experiences include leadership positions at Schering-Plough Research Institute and Organon, where Ronald managed departments and sections responsible for both early and late-stage development of sterile drug products. Ronald earned a PhD in Biochemistry from Radboud University in 1997.
This person is not in any teams
Byondis
1 followers
With a passion for outsmarting relentless cancers and autoimmune diseases, Byondis takes precision medicines to the next level. We are driven by one goal: providing novel treatments with high efficacy and low systemic toxicity for patients with high unmet medical needs. Many companies work in the areas of unmet need. What differentiates Byondis is its focus on producing a broad spectrum of molecular concepts, ranging from small molecule chemistries to complex protein structures. We engineer smaller and larger molecular functionalities that may be combined to target the right part of the body. This involves: • Next generation antibody-drug conjugates (ADCs), including proprietary linker-drug (LD) technology to generate multiple ADC candidates targeting different indications • Site-specific conjugation technology • Monoclonal antibodies (mAbs) • Highly selective, disease-targeting small molecules The success of our company fully depends on our people. To them, we aim to provide a fair, open and inspiring working environment, where there is room for ambition, entrepreneurship and new initiatives leading to new medicines that save and transform patients’ lives.